Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02107560
Other study ID # SNUBH-IMGPB-2014-01
Secondary ID
Status Terminated
Phase N/A
First received April 3, 2014
Last updated May 23, 2016
Start date April 2014
Est. completion date March 2016

Study information

Verified date April 2014
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Observational

Clinical Trial Summary

Cholangitis is a complication of biliary statsis. Bile juice is sterile when there is no obstruction, however, it can be infected with bacteria when there is a stasis or obstruction. After infection, cholangitis can be developed because of systematic endotoxemia or bacteremia. Though identification of bacteria is very important for selection of adequate antibiotics, treatment with empirical antibiotics is commonly performed when identification of bacteria is not possible.

Identification of bacteria is usually done with blood or bile culture. In the previous studies, the same results from blood and bile were common in patients with cholangitis. However, the data of these studies were based on the bile juice which was aspirated by surgery. Considering that bile duct obstruction is usually treated with endoscopy or radiological intervention without surgery, it is necessary to collect data with endoscopic or radiologic intervention. In addition, the concordant rate of these two tests has not been reported according to severity of cholangitis. As a result, the necessities of bile and blood culture are not agreed among experts in this fields.

Our hypothesis is that concordant rates of bile and blood culture are same in patients with each moderate or severe cholangitis. However, the concordant rates of bile and blood culture are different between patients with moderate and severe cholangitis. This study will assess the positive rates of blood and bile culture in patients with moderate or severe cholangitis, respectively and compare the results according to the different severity.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with moderate or severe cholangitis which fullfilled the criteria by the Tokyo Guidelines (Tanaka A, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007;14:59-67.)

- Patients who are successfully treated with endoscopic or radiologic biliary drainage

- Patients who undergo both blood and bile culture tests

Exclusion Criteria:

- Patients with other infections except cholangitis or cholecystitis

- Patients who received surgical biliary drainage treatment

- Patients who are treated with endoscopic or radiologic biliary drainage more than 24 hours after using initial antibiotics

- Patients who does not agree with informed consent or who are vulnerable subjects

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam Gyeonggi-do

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postive culture rates of blood and bile juice Cultures results of blood and bile juice in patients with cholangitis are usually reported within 1 week after test in our hospital. After the completion of study, we will analyze the positive culture rates in each samples and compate those each other. In addition, we will compare the results according to the severity of cholangitis. 1 week after culture test No
Secondary Identification of bacterial species in blood and bile cultures Cultures results of blood and bile juice in patients with cholangitis are usually reported within 1 week after test in our hospital. After the completion of study, we will analyze the bacterial species in each samples and compate those each other. 1 week after culture test No
Secondary Identification of antibiotics sensitive and resistant bacterial species Cultures results of blood and bile juice in patients with cholangitis are usually reported within 1 week after test in our hospital. After the completion of study, we will analyze the antibiotics sensitive and resistant bacterial species in each samples and compate those each other. 1 week after culture test No
Secondary Identification of colonized bacterial species Cultures results of blood and bile juice in patients with cholangitis are usually reported within 1 week after test in our hospital. After the completion of study, we will analyze the colonized bacterial species which is not true pathogens in each samples and compate those each other. 1 week after culture test No
See also
  Status Clinical Trial Phase
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Withdrawn NCT02543957 - Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
Completed NCT02461147 - Prospective Validation of "Cholecystectomy First" Strategy for Gallstone Migration
Completed NCT01824186 - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy N/A
Terminated NCT00990366 - Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve N/A
Completed NCT02594891 - Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis N/A
Terminated NCT01142921 - The Patency Period of the New Plastic Anti-reflux Biliary Stent N/A
Completed NCT03104582 - Best Biliary Drainage Option in Advanced Klatskin Tumor N/A
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Terminated NCT02034279 - The INFECIR-2 Albumin Prevention Study Phase 4
Completed NCT04671095 - Single Use ERCP Performance -SURE Study
Recruiting NCT03087656 - Antibiotics to Decrease Post ERCP Cholangitis Phase 4
Completed NCT02098486 - Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP Phase 2
Withdrawn NCT03678480 - A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC) Phase 2
Recruiting NCT04216745 - Microbial Analysis in Patients With Cholangitis
Recruiting NCT03133026 - Cholangioscopic Assessment of Occluded Biliary Stent and Role of Biliary Radiofrequency Ablation N/A
Terminated NCT02618668 - Haemodynamic Stability of Ketamine/Propofol Admixture "Ketofol" in Patient Undergoing Endoscopic Retrograde Cholangio Pancreatography Phase 2
Recruiting NCT01438385 - Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders N/A
Recruiting NCT05750966 - Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis N/A
Recruiting NCT06111872 - Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography. Phase 2